Blog | Page 9 of 33 | Oncotarget

Oncotarget News

Figure 4: Correlation matrix with numerous significant positive correlations.

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning

February 14, 2024

Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”BUFFALO, NY- February 14, 2024 – A new research paper was published in... read more

Oncotarget

Differential Expression of Mad2 Gene in Human Esophageal Cancer

February 12, 2024

people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the... read more

Figure 1: Ruxolitinib exerts its anti-myeloma effects through several mechanisms.

Oncotarget

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

February 7, 2024

the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as... read more

Figure 1: A typical drug discovery and development strategy.

Oncotarget

Drug Discovery in Academia; Dumping in the Publication Landfill?

February 5, 2024

fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”BUFFALO, NY- February 5, 2024 – A new editorial paper... read more

Figure 2: BCAS1+ cells in diffuse gliomas are morphologically different from BCAS1+ cells in healthy brain tissue.

Oncotarget

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients

January 31, 2024

this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”BUFFALO, NY- January 31, 2024 – A new research paper was published in... read more

Figure 1: Representative histopathologic slides stained with hematoxylin and eosin of thyroid cancer from well-differentiated to dedifferentiated states.

Oncotarget

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation

January 29, 2024

An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.”BUFFALO, NY- January 29, 2024 – A new research perspective was published... read more

Figure 1: Treatment timeline with chest computed tomography (CT) and brain magnetic resonance images (MRI) on osimertinib.

Oncotarget

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease

January 24, 2024

this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”BUFFALO, NY- January 24, 2024 – A new case report was published... read more

Figure 1: Histological analysis of iliac crest bone biopsy.

Oncotarget

Bone Marrow Adipocytes Provide Early Sign of Progression from MGUS to Multiple Myeloma

January 22, 2024

bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”BUFFALO, NY- January 22, 2024 – A new... read more

PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

Oncotarget

Dr. Blagosklonny’s Battle With Cancer (Part 1)

January 22, 2024

Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.”BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail... read more

Oncotarget

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

January 17, 2024

this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January... read more